| Title | Management of patients with peptic ulcer receiving streptokinase for acute myocardial infarction | |
| Authors | John Kanonidis, Constantine Papadopoulos, John Papayannis, Stavros Konstantinidis, Stylianos Savatis, Panayotis Kotridis, Constantine Gitsios and George Sakadamis
2nd Department of Cardiology, University of Thessaloniki, Greece |
|
| Citation | Kanonidis, J., Papadopoulos, C., Papayannis, J., Konstantinidis, S., Savatis, S. et al.: Management of patients with peptic ulcer receiving streptokinase for acute myocardial infarction, Epitheorese Klin. Farmakol. Farmakokinet. 5(3): 143-147 (1991) | |
| Publication Date | Received for publication: 25 October 1991
Accepted for publication: 5 November 1991 |
|
| Full Text Language | English | |
| Order – Buy | Ηλεκτρονική Μορφή: pdf (10 €) – Digital Type: pdf (10 €)
pharmakonpress[at]pharmakonpress[.]gr |
|
| Keywords | Acute myocardial infarction, streptokinase, peptic ulcer. | |
| Other Terms | review article | |
| Summary | The aim of this study is to evaluate the role of H2 inhibitors in preventing gastrointestinal bleeding (GIB) in patients (pts) with peptic ulcer (PU) undergoing thrombolysis for acute myocardial infarction (AMI). Thirty nine pts (mean age 57±6 years) with known PU, receiving streptokinase (SK) for AMI, were studied. These pts were divided in two groups (G). G1 included 22 pts who had been free from symptoms of PU for at least six months prior to AML G2 included 17 pts, 8 with relapsing symptoms of PU for the six month period prior to AMI and 9 with a history of PU complications. As a supplement to thrombolytic treatment, pts in G1 received Ranitidine 150 mgr per os t.i.d. for one week and in G2 Ranitidine 50 mgr i.v. t.i.d. for 3 days, followed by 150 mgr per os t.i.d. up to the end of the first week. No pts developed clinically recognizable GIB. In 5 pts (2 in G1 and 3 in G2) a noticeable decrease of Hb occurred without clinical evidence of blood loss. In 7 pts (4 in G1 and 3 in G2) adverse reactions from the gastrointestinal system (vomiting, nausea) were attributed to hypersensitivity to SK infusion. In conclusion, a protective role of H2 inhibitors, although. cannot be claimed due to the non randomised nature of the study, is nevertheless strongly indicative and can be recommended for those pts with PU which are considered at high risk for GIB. | |
| References | 1. Μarder, V.J., Sherry, S.: Thrombolytic Therapy: Current status. N. Engl. J. Med. 378: 1512 (1988)
2. Yusuf, S., Collins, R., Peto, R. et al: Intravenous and intracoronary fibrinolytic therapy in acute myocardial infarction: Overview of results on mortality, reinfarction and side-effects from 33 randomised controlled trials. Eur. Heart J. 556 (1985) 3. Lijnen, H.R., Collen, D.: Molecular mechanisms of thrombolytic therapy. Hemostasis 16 (Suppl. 3J: 3 (1986) 4. Isselbacher, J.K., Popp, W.J. Jr.: Hematemesis and melena. In: Harrison’s Principles of Internal Medicine, p. 202, McGraw-Hill International Book Company, 1981 5. McGuigan, E.J.: Peptic ulcer. In: Harrison’s Principles of Internal Medicine, p. 1371, McGraw-Hill International Book Company, 1981 6. The GISSI Study Group: Effectiveness of intravenous thrombolytic treatment in acute myocardial infarction. Lancet i: 397 (1986) 7. AIMS Trial Study Group: Effect of intravenous APSAC on mortality after myocardial infarction. Lancet i: 545 (1988) 8. GISSI-2: A factor randomised trial of alteplase versus streptokinase and heparin versus no heparin among 12490 patients with acute myocardial infarction. Lancet 336: 65 (1990) 9. TIMI: Thrombolysis in Myocardial Infarction (TIMI) Trial. Phase I: a comparison between intravenous tissue plasminogen activator and intravenous streptokinase. Circulation 76: 142 (1987) 10. ISAM Study Group: A prospective trial of intravenous streptokinase in acute myocardial infarction (I.S.A.M.). Mortality, morbidity and infarct size at 21 days. N. Engl. J. Med. 314: 1465 (1986) 11. Wilcox, R.G., Von Der Lippe, G., Oisson, C.G. et al for the ASSET Study Group: Trial of tissue plasminogen activator for mortality reduction in acute myocardial infarction. Anglo-Scandinavian Study of Early Thrombolysis (ASSET). Lancet ii: 525 (1988) 12. The European Cooperative Study Group: Streptokinase in acute myocardial infarction. Extendend report of the European Cooperative Trial. Acta Med. Scand. 210 (Suppl. 648): 7 (1981) |
|
| Relative Papers |
Online ISSN 1011-6575
Άρθρα Δημοσιευμένα σε αυτό το Περιοδικό Καταχωρούνται στα:
- Chemical Abstracts
- Elsevier’s Bibliographic Databases: Scopus, EMBASE, EMBiology, Elsevier BIOBASE SCImago Journal and Country Rank Factor
Articles published in this Journal are Indexed or Abstracted in: • Chemical Abstracts • Elsevier’s Bibliographic Databases: Scopus, EMBASE, EMBiology, Elsevier BIOBASE SCImago Journal and Country Rank Factor
Συντακτικη Επιτροπή-Editorial Board
| ΕΤΗΣΙΑ ΣΥΝΔΡΟΜΗ 1991 – ANNUAL SUBSCRIPTION 1991 | |
| Γλώσσα Πλήρους Κειμένου – Full Text Language | Αγγλικά – English |
| Παραγγελία – Αγορά – Order – Buy | Ηλεκτρονική Μορφή: pdf (70 €) – Digital Type: pdf (70 €)
pharmakonpress[at]pharmakonpress[.]gr |
| Έντυπη Μορφή (70 € + έξοδα αποστολής) – Printed Type (70 € + shipping)
pharmakonpress[at]pharmakonpress[.]gr |
|